|
|
|
|
|
SINGAPORE, Oct 24, 2017 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that U.S. biomedical subsidiary Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
Global Biolife has established a collaboration with top U.S. candy manufacturer Quality Candy Company LLC for the development, manufacture and global distribution of Laetose.
Developed by Mr Daryl L.Thompson, Global BioLife Director of Scientific Initiatives, Laetose is a functional sugar with a 30% to 50% lower calorie-count than regular sugar, possesses low glycemic properties, and also assists in mitigating inflammatory responses.
According to a World Health Organisation report released in Oct '17, the number of obese children aged 5 to 19 rose globally more than ten-fold from 11mil in 1975 to 124mil in 2016. The World Health Organisation report said that countries should seek to reduce consumption of cheap, ultra-processed, calorie-dense nutrition-poor foods.
Studies have shown that excessive sugar consumption is the primary cause of modern diseases such as cardiovascular disease, Type-2 diabetes, metabolic syndrome and obesity. While sugar is not toxic, the human body perceives it as such and, in turn, initiates pro-inflammatory responses. Laetose could help mitigate such reactions by reducing the rate of glucose absorption throughout the body.
Quality Candy has a Safe Quality Food ("SQF") Level 3 - Excellent certified manufacturing facility and is a leading manufacturer and distributer of high-quality candy with distribution in locations across the globe. They will utilize their state-of-the-art facility and expertise to manufacture Laetose according to the unique formula discovered by Global BioLife.
"In this day and age, we should be exploring ways to make smarter foods. Our Laetose modified sugar has been designed specifically for this purpose," said Global BioLife's Mr Thompson, a pioneering natural products scientist cited, amongst others, for his achievements in organic and carbohydrate chemistry.
Mr Chan Heng Fai, Executive Chairman of SeD, said: "Cardiovascular disease, Type-2 diabetes, metabolic syndrome and obesity have become a global epidemic. SeD has invested in Global BioLife as a think tank designed to research and develop smarter consumer products to reverse or mitigate this growing trend."
"Quality Candy has been on a quest for over a decade, looking for a natural sugar substitute," said Mr Jim Gist, Chief Revenue Officer of Quality Candy. "This product is finally the breakthrough our industry needed to improve existing reduced-calorie and sugar-free products and help consumers around the world live a healthier lifestyle."
The market for a safe and affordable alternative to sugar is growing due to increasing awareness of health risks associated with the excessive consumption of refined sugar. Although Laetose is marketed as an alternative usable in everything from baking to cooking, and as a tabletop sweetener, the ultimate goal is to infuse Laetose into the multibillion-dollar beverage industry. Unlike other natural-based and artificial sweeteners widely used in beverages, Laetose's unique patent-pending formula has no aftertaste.
"Due to the perceived toxicity of prolonged use of artificial sweeteners and the inability to use them as a direct replacement for sugar in baking and many beverages, we believe our product will have a direct advantage. We believe that the world is looking for a way to maintain sweetness while avoiding the negative effects of sugar and we intend to provide the solution," Mr Thompson added.
Dr Peggy Tang, Global BioLife CEO, said: "Laetose is our first step in creating smarter foods. We have confidence that our collaboration with industry leader Quality Candy will enable us to accomplish our goal."
About Singapore eDevelopment Ltd (SGX:40V)
Incorporated on 9 Sept 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd [SGE.SP; SINE.SP] is involved in property development and investment primarily in the United States and Western Australia; information technology-related businesses; development, research, testing, manufacturing, licensing and distribution of biomedical products; and investment activities. For more information, please visit www.SeD.com.sg or mail : contact@SeD.com.sg.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., in turn a wholly-owned direct subsidiary of Singapore eDevelopment Ltd, a company listed on the Singapore Exchange. The remaining shares of Global BioLife Inc. are held by Global Research & Discovery Group Scientific LLC ("GRDGS") and ASX-listed Holista CollTech Ltd with 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDGS and Holista, GBLI pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com.
Topic: Research and development
Source: Alset International Ltd
Sectors: BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Alset International Ltd |
| Mar 23, 2022 09:00 HKT/SGT |
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
| Feb 21, 2022 12:00 HKT/SGT |
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
| Oct 5, 2020 15:25 HKT/SGT |
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
| Sept 18, 2020 17:00 HKT/SGT |
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
| July 31, 2020 15:00 HKT/SGT |
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
| June 24, 2020 14:00 HKT/SGT |
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
| June 17, 2020 18:00 HKT/SGT |
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
| June 1, 2020 13:00 HKT/SGT |
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
| Apr 24, 2020 10:00 HKT/SGT |
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
| Mar 18, 2020 11:00 HKT/SGT |
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
| More news >> |
 |
|
|
|
